Role of carbonic anhydrase in bone: Partial inhibition of disuse atrophy of bone by parenteral acetazolamide
- 49 Downloads
Carbonic anhydrase inhibitor acetazolamide blocks the hypercalcemic response to parathyroid hormone (PTH) and to dibutyrul 3′,5′-cyclic AMP in the nephrectomized-parathyroidectomized rat. In addition, we have reported that acetazolamide, when incorporated in the diet, partially prevents denervation-induced bone loss in a rat model of disuse osteoporosis. The present study compares the effectiveness of orally and subcutaneously administered acetazolamide in preventing denervation-induced bone loss in the rat model. The rats were treated with acetazolamide either orally, by incorporation in the diet of concentrations of 0.2, 0.5, or 1.5% for 15 days, or parenterally by two different subcutaneous methods of administration. The latter included either injection twice daily for 15 days or continuous infusion for 8 days using an osmotic minipump. It was found that parenteral administration was as effective in partially preventing denervation-induced bone mass changes as oral administration. In addition, protection by the parenteral route could be accomplished with much smaller daily doses; continuous infusion required the least daily dose. Approximately 50% protection was observed to occur with daily doses of 1,094, 129, and 8 mg/kg body weight for the oral, subcutaneous injection, and subcutaneous infusion routes respectively. These findings are consistent with our concept that carbonic anhydrase plays a significant role in bone metabolism.
Key wordsAcetazolamide Denervation-induced bone loss Oral ingestion Subcutaneous injection Continuous subcutaneous infusion
Unable to display preview. Download preview PDF.
- 1.Waite LC, Kenny AD (1970) Acetazolamide and calcium metabolism in the rat. In: Taylor S, Foster GV (eds) Calcitonin 1969. William Heinemann Medical Books Ltd, London, p 442Google Scholar
- 4.Simasaki M, Yagi T (1960) Histochemistry of carbonic anhydrase with special reference to the osteoclast. Dent Bull Osaka Univ 1:89–98Google Scholar
- 8.Hall GE, Kenny AD (1983) Parathyroid hormone increases carbonic anhydrase activity in cultured mouse calvaria. Calcif Tissue Int 35:682Google Scholar
- 13.Kenny AD (1978) Protective effect of parenteral acetazolamide in a rat model of disuse atrophy of bone. Pharmacologist 20:152Google Scholar
- 15.Snedecor GW (1956) Statistical methods, Iowa State College Press, AmesGoogle Scholar
- 17.Hall GE, Kenny AD (1984) The role of carbonic anhydrase in dibutyryl cyclic AMP-induced bone resorption. Abstracts of the 40th Southwest Regional American Chemical Society Meeting, p 40Google Scholar
- 18.Gunasekaran S, Hall GE, Kenny AD (1984) Effect of forskolin on neonatal mouse bone metabolismin vitro. Abstracts of the 40th Southwest Regional American Chemical Society Meeting, p 40Google Scholar
- 19.Frost HM (1983) Pharmacology and the osteoporoses: a field in flux. Meth Find Exp Clin Pharmacol 5:5–16Google Scholar
- 20.Kenny AD, Yee JA, Lutherer LO (1979) Inhibition of disuse atrophy of bone in rats by continuous subcutaneous infusion of acetazolamide. Calcif Tissue Int 28:157Google Scholar
- 24.Sly WS, Hewett-Emmett D, Whyte MP, Yu Y-SL, Tashian RE (1983) Carbonic anhydrase II deficiency identified as the primary defect in the autosomal recessive syndrome of osteopetrosis with renal tubular acidosis and cerebral calcification. Proc Natl Acad Sci USA 80:2752–2756PubMedCrossRefGoogle Scholar